

Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial

Aniek E.M. Schouten, MSc¹ ; Anouk E. Hiensch, PhD¹ ; Geert W.J. Frederix, PhD¹; Evelyn M. Monninkhof, PhD¹ ; Martina E. Schmidt, PhD² ; Dorothea Clauss, PhD³ ; Nadira Gunasekara, MSc⁴; Jon Belloso, PhD⁵; Mark Trevaskis, BSc⁶ ; Helene Rundqvist, PhD⁷ ; Joachim Wiskemann, PhD⁸ ; Jana Müller, PhD⁹ ; Maïke G. Sweegers, PhD¹⁰; Carlo Fremd, MD, PhD¹¹; Renske Altena, MD, PhD¹² ; Rhodé M. Bijlsma, MD, PhD¹³ ; Gabe Sonke, MD, PhD¹⁴ ; Ainhara Lahuerta, MD, PhD⁵; G. Bruce Mann, MD, PhD¹⁵ ; Prudence A. Francis, MD¹⁶ ; Gary Richardson, MD¹⁷ ; Wolfram Malter, MD, PhD¹⁸ ; Joanna Kufel-Grabowska, MD, PhD¹⁹; Elsken van der Wall, MD, PhD¹³ ; Neil K. Aaronson, PhD²⁰ ; Elzbieta Senkus, MD, PhD²¹; Ander Urruticoechea, MD, PhD⁵ ; Eva M. Zopf, PhD^{17,22}; Wilhelm Bloch, PhD³; Martijn M. Stuiver, PhD¹⁰ ; Yvonne Wengstrom, PhD²³; Karen Steindorf, PhD² ; Miriam P. van der Meulen, MD, PhD¹; and Anne M. May, PhD¹ 

DOI <https://doi.org/10.1200/JCO-24-01441>

ABSTRACT

PURPOSE To evaluate the cost utility of a 9-month supervised exercise program for patients with metastatic breast cancer (mBC), compared with control (usual care, supplemented with general activity advice and an activity tracker). Evidence on the cost-effectiveness of exercise for patients with mBC is essential for implementation in clinical practice and is currently lacking.

METHODS A cost-utility analysis was performed alongside the multinational PREFERABLE-EFFECT randomized controlled trial, conducted in 8 centers across Europe and Australia. Patients with mBC (N = 357) were randomly assigned to either a 9-month, twice-weekly, supervised exercise group (EG) or control group (CG). Costs of the exercise program were calculated through a bottom-up approach. Other health care resource use, productivity losses, and quality of life were collected using country-adapted, self-reported questionnaires. Analyses were conducted from a societal perspective with a time horizon of 9 months. Costs were collected and reported in 2021 Euros (€1 = \$1.18 US dollars).

RESULTS Compared with the CG, EG resulted in a quality-adjusted life-year (QALY) gain of 0.013 (95% CI, -0.02 to 0.05) over a 9-month period. The mean costs of the exercise program were €1,696 per patient with one-on-one supervision (scenario 1) and €609 with one-on-four supervision (scenario 2). These costs were offset by savings in health care and productivity costs, resulting in mean total cost differences of -€163 (scenario 1) and -€1,249 (scenario 2) in favor of EG. The probability of supervised exercise being cost-effective was 65% in scenario 1 and 91% in scenario 2 at a willingness-to-pay threshold of €20,000 per QALY.

CONCLUSION Exercise for patients with mBC increases quality of life, decreases costs, and is likely to be cost-effective. Group-based supervision is expected to have even higher cost-savings. Our positive findings can inform reimbursement of supervised exercise interventions for patients with mBC.

ACCOMPANYING CONTENT

 [Data Sharing Statement](#)

 [Data Supplement](#)

 [Protocol](#)

Accepted November 22, 2024

Published January 13, 2025

J Clin Oncol 43:1325-1336

© 2025 by American Society of Clinical Oncology



[View Online Article](#)

Creative Commons Attribution
Non-Commercial No Derivatives
4.0 License

INTRODUCTION

Survival rates are improving for patients with metastatic breast cancer (mBC) because of therapeutic advances.¹⁻³ Consequently, the focus is shifting toward maintaining health-related quality of life (HR-QoL) and reducing treatment-related side effects.⁴ Abundant evidence supports

the effectiveness of exercise in achieving these goals in the curative setting.^{5,6} However, evidence in the advanced disease setting is scarce. Recently, the multinational PREFERABLE-EFFECT study demonstrated that a 9-month supervised exercise program is also an effective and safe strategy for alleviating fatigue and other burdensome side effects of treatment, and for improving HR-QoL in patients with mBC.⁷

CONTEXT

Key Objective

Is a 9-month supervised exercise program cost-effective compared with control (ie, usual care supplemented with physical activity advice and activity tracker) for patients with metastatic breast cancer (mBC)?

Knowledge Generated

In this multinational randomized clinical trial including 357 patients with mBC, supervised exercise is dominant; quality-adjusted life-years increased by 0.013 (95% CI, -0.02 to 0.05) with cost-savings of €163 (\$192 US dollars [USD]; 95% CI, -€1,901 to €2,228) or €1,249 (\$1,474 USD; 95% CI, -€817 to €3,315) per patient, when supervised one-on-one or one-on-four, respectively.

Relevance (S.B. Wheeler)

These data can inform arguments for reimbursement and scale-up for supportive physical activity interventions for people with cancer, though these programs should be tested in a variety of settings to confirm their cost-benefit.*

*Relevance section written by JCO Associate Editor Stephanie B. Wheeler, PhD, MPH.

The global economic costs of mBC are expected to increase from \$63.4 billion US dollars (USD) in 2015 to \$152.4 billion USD in 2030.^{8,9} To keep cancer care affordable, investment in supportive care strategies represents one approach to controlling the cancer burden by reducing disease and treatment-related side effects.¹⁰ Thorough economic evaluations of supportive care strategies are needed to inform decision making.¹⁰ To date, research has focused primarily on the efficacy and effectiveness of exercise in cancer care, while little is known about its cost-effectiveness. Evidence regarding the cost-effectiveness remains inconclusive because of the scarcity and moderate quality of studies, as well as the heterogeneity in the type of exercise delivered and the type of analyses used for the economic evaluation.^{11,12} Moreover, to our knowledge, none of the existing studies have included patients with mBC. Hence, we aimed to assess the cost-effectiveness of a 9-month exercise program compared with control (usual care, supplemented with general activity advice and an activity tracker) in patients with mBC alongside the PREFERABLE-EFFECT study.

METHODS

In this economic evaluation alongside the multinational PREFERABLE-EFFECT study,¹³ the costs and quality-adjusted life-years (QALYs; Data Supplement, Table S1, online only) of patients with mBC participating in a supervised exercise program were compared with a control group (CG). The evaluation was performed from both a societal perspective and a health care perspective with a 9-month time horizon, matching the intervention period. No discounting was required. Reporting followed the CHEERS 2022 checklist.¹⁴

PREFERABLE-EFFECT Study

This two-arm randomized controlled trial (RCT) was conducted at eight study centers in Germany (n = 89), the

Netherlands (n = 91), Spain (n = 54), Sweden (n = 44), Poland (n = 44), and Australia (n = 35). The study protocol was approved by the institutional review board of the University Medical Center Utrecht, the Netherlands, and by the local ethical review boards of all participating institutions. It was registered at ClinicalTrials.gov (identifier: [NCT04120298](https://clinicaltrials.gov/ct2/show/study?term=NCT04120298)). After providing written informed consent, patients with mBC with a life expectancy of ≥6 months and without unstable bone metastases were randomly assigned (stratified by study center and therapy line) to a supervised exercise intervention (exercise group) or to the control group. Both groups received usual care and an activity tracker. CG received written information on physical activity guidelines (ie, 150 minutes of aerobic exercise and two-three sessions of resistance exercise per week). The exercise group (EG) received a 9-month multimodal exercise program, which included resistance, aerobic, and balance exercises, and consisted of twice-weekly supervised exercise sessions of 1 hour for the first 6 months. For the last 3 months, 1 weekly supervised session was replaced by an unsupervised session to facilitate the transition to self-directed exercise after 9 months. Supervision was provided by qualified exercise professionals (Data Supplement, Table S2).

Recently, the results for the primary end points of the RCT were published.⁷ Between 2020 and 2022, 357 patients were enrolled and randomly assigned into EG (n = 178) or CG (n = 179; [Fig 1](#)). Mean age of the participants was 55.4 years (SD = 11.1), the majority were female (99.4%), 44.8% had a paid job, was receiving first/second line of treatment (74.8%), and had bone metastases (67.2%; Data Supplement, Table S3).

Data Collection

The validated (across different populations, settings, and disease conditions, including breast cancer [BC]) EuroQol 5-




FIG 1. CONSORT diagram. Flow of participants through the study.

dimension questionnaire (EQ-5D-5L),¹⁵⁻¹⁷ iMTA Medical Consumption Questionnaire (iMCQ), and iMTA Productivity Cost Questionnaire (iPCQ) were completed by participants at baseline (only EQ-5D-5L), and 3, 6, and 9 months. The exercise intervention costs were calculated using a bottom-up method (Data Supplement, Table S1). Data on costs were collected and reported in 2021 Euros (average 2021 exchange rate: €1 = \$1.18 USD).

Resource Use and Costs

Supervised Exercise Program

Centers where the exercise program was performed completed a data collection sheet documenting personnel and equipment costs (Data Supplement, Table S4). Details on facility rent were insufficient to calculate overhead. Therefore, overhead costs (ie, capital overhead, management, and other noncare staff) were estimated to be 4.4%, on the basis of estimations in the Unit Costs of Health and Social Care 2022 manual of the UK and Dutch guidelines for health economic evaluations.^{18,19} Group sizes per exercise session differed per country, ranging from one to five participants (Data Supplement, Table S2). For the purpose of informing

decision making on implementing exercise in clinical practice, we considered two scenarios for group size: (1) one-on-one supervision and (2) one-on-four supervision. We included the one-on-one scenario to examine cost-effectiveness in settings where larger group sizes are not feasible (eg, regions with low population density), and we consider the one-on-four scenario to reflect clinical practice since most participants exercised in groups. We assumed that group size would not affect the quality of the session and, thus, not affect QALYs. The number of exercise sessions per participant was derived from attendance logs, with a cutoff value of 60 sessions (ie, the maximum number of sessions offered during the study). Costs were estimated per participant, with country-specific wages obtained from each participating center. Costs of the activity tracker (€75) were added for each participant in both EG and CG.

Other Health Care Resource Use

Health care consumption was measured using an adjusted version of the iMCQ,²⁰ and included information on hospital resource use (eg, hospitalizations, outpatient visits, and emergency visits) and extramural care (eg, general practitioner visits, physiotherapy for reasons other than the

exercise program, and home and informal care). More information on how costs were calculated can be found in the Data Supplement (Methods S1 and Table S5).

In the Netherlands, exercise sessions were supervised by a physiotherapist. If participants reported exercise sessions as physiotherapy visits, the number of physiotherapy visits was set to 0 ($n = 13$ participants). For home and informal care, responses were capped at 16 hours/day.²¹ Other extreme values were checked by either contacting the participant or checking the participant's medical record.

Indirect Costs

Productivity losses of paid work, including short-term absenteeism, long-term absenteeism, and presenteeism, were measured using the iPCQ.²² Labor costs were estimated using country-specific hourly compensation of employees.²³ More information on how costs were calculated can be found in the Data Supplement (Methods S1 and Table S6).

Quality-Adjusted Life-Years

QALYs were estimated by combining utility values from the EQ-5D-5L with mortality data. Utility scores represent HR-QoL, in which 0 corresponds to death and 1 corresponds to perfect health. A single value set was applied to estimate utility scores.²⁴ The German value set²⁵ was chosen as a high number of participants are German and the mean utility score fell between the mean scores of the other value sets. If a participant died, utility scores were zero from their date of death. The QALYs over 9 months were calculated using an AUC approach with linear interpolation (Data Supplement, Table S1).²⁶

Cost-Utility Analysis

Statistical analysis was performed with R (R Foundation for Statistical Computing), version 4.3.1. In total, 12%, 14%, and 15% of responses were missing for the iMCQ and the EQ-5D-5L at 3, 6, and 9 months, respectively, and 16%, 20%, and 22% for the iPCQ, excluding missing values due to death. Missing data were handled with multiple imputation ($m = 10$), using the R MICE-package (Data Supplement, Table S7).^{27,28} Bootstrapping (5,000 iterations) was used to estimate outcome uncertainty.²⁸ Two seemingly unrelated regressions²⁸ were used to estimate incremental costs and QALYs, adjusted for stratification factors. Incremental QALYs were additionally adjusted for baseline utility score. Effect sizes (ES) were calculated using Cohen's d -statistic.²⁹ Cost-effectiveness planes (CE-plane) and cost-effectiveness acceptability curves (CEAC) were constructed. The probability of cost-effectiveness was estimated for the upper and lower limits of the willingness-to-pay thresholds (WTP) of the Netherlands (€20,000 and €80,000/QALY), which encompass the thresholds used by other countries.³⁰⁻³³

The two base case analyses (Data Supplement, Table S1) were (1) one-on-one supervision, societal perspective; and (2) one-on-four supervision, societal perspective. Three scenario analyses (Data Supplement, Table S1) were included: (1) one-on-one supervision, health care perspective; (2) one-on-four supervision, health care perspective; and (3) supervision using group size in the trial, societal perspective. The health care perspective excludes costs related to productivity losses and informal care. Additional scenario analyses where all participants were considered Dutch (unit costs and EQ-5D-5L value set) can be found in the Data Supplement (Table S8). Analyses were performed according to the intention-to-treat principle and Dutch guidelines of health economic evaluations.^{19,34}

RESULTS

Costs

The mean 9-month costs of the exercise program per participant were €1,696 when supervised one-on-one, and €609 when supervised one-on-four (Table 1) for an average of 40.5 sessions. Session costs can be found in the Data Supplement (Table S9).

Compared with CG, mean health care costs over 9 months were lower in EG for home care (€93 v €468), day treatments (€2,105 v €2,437), and hospital visits (€1,097 v €1,311). For EG, higher mean costs were found for physiotherapy (€294 v €241). Violin plots showed an outlier for home care in CG, but similar distributions for other costs (Data Supplement, Fig S1). Throughout the study, working hours decreased in both groups (Table 2). Productivity costs for short-term absenteeism were lower in EG compared with control (€1,202 v €1,637).

Total costs were €9,700 for CG and €9,568 for EG when supervised one-on-one (adjusted difference: -€163), and €8,482 for EG when supervised one-on-four (adjusted difference: -€1,249). Country-specific resource use can be found in the Data Supplement (Table S10-S15).

Quality of Life

Compared with CG, EG had higher utility values at baseline, and at 3, 6, and 9 months (mean between-group difference 0.016 [95% CI, -0.010 to 0.042, ES = 0.13], 0.020 [95% CI, -0.034 to 0.074, ES = 0.16], 0.048 [95% CI, -0.016 to 0.112, ES = 0.39], and 0.029 [95% CI, -0.049 to 0.106, ES = 0.23], respectively; Table 3). Mean utility values decreased over the 9-month intervention period for both CG and EG, from 0.871 to 0.715 in CG and 0.887 to 0.744 in EG. Mean (SE) QALYs after 9 months, adjusted for baseline utility scores, were 0.606 (0.011) in EG and 0.591 (0.012) in CG (difference = 0.013 QALY [95% CI, -0.017 to 0.046]). This corresponds to an additional 5 days in perfect health over 9 months in favor of EG.

TABLE 1. Costs (€, 2021) After Multiple Imputation for EG and CG Over 9 Months

Cost	EG (n = 178)			CG (n = 179)			
	People, No. ^a	HCU, Mean No. ^b	Mean Cost	People, No. ^a	HCU, Mean No. ^b	Mean Cost	Mean Cost Difference ^c
Intervention costs							
Scenario one-on-one ^c	162	40.5 visits	€1,771	179	0 visits	€75	€1,696
Scenario one-on-four ^d	162	40.5 visits	€684	179	0 visits	€75	€609
Direct health care costs							
GP	152	5.6 visits	€182	151	5.8 visits	€192	−€10
Physiotherapy	110	10.1 visits	€294	115	7.7 visits	€241	€53
Dietician	51	0.5 visits	€12	55	0.6 visits	€16	−€4
Social worker	53	0.6 visits	€41	57	0.5 visits	€32	€9
Psychologist	77	2.4 visits	€221	87	2.6 visits	€228	−€7
Occupational therapy	26	0.4 visits	€13	46	0.5 visits	€17	−€4
Acupuncture	63	1.2 visits	€73	71	1.8 visits	€111	−€38
Hospital							
Hospital admissions	62	1.8 days	€1,097	64	2.3 days	€1,311	−€214
Outpatient visits	168	8.9 visits	€1,151	169	10.1 visits	€1,311	−€160
Day treatments	145	7.5 visits	€2,105	155	8.8 visits	€2,437	−€332
A&E	53	0.4 visits	€101	75	0.5 visits	€143	−€42
Other							
Home care	29	4.1 hours	€93	43	17.2 hours	€468	−€375
Total direct health care costs		€5,363			€6,485	−€1,122	
Indirect health care costs							
Informal care	86	57.0 hours	€736	108	79.6 hours	€961	−€225
Indirect non-health care costs							
Temporary absenteeism	55	36.4 hours	€1,202	65	53.0 hours	€1,637	−€435
Long-term absenteeism	20	11.7 hours	€344	23	11.1 hours	€351	−€7
Presenteeism	47	4.7 hours	€131	71	5.8 hours	€168	−€37
Total costs							
Scenario one-on-one ^d	178	—	€9,568	179	—	€9,700	−€132
Scenario one-on-four ^e	178	—	€8,482	179	—	€9,700	−€1,218

Abbreviations: A&E, accidents and emergency; CG, control group; EG, exercise group; GP, general practitioner; HCU, health care usage.

^aNumber of participants with an average health care usage >0 after multiple imputation.

^bAverage health care usage of all participants, including those who indicated 0 visits/days/hours.

^cUnadjusted for treatment center and line of treatment.

^dOne-on-one, with supervision for 75% of the exercise session.

^eOne-on-four, with supervision during the entire exercise session (100%).

TABLE 2. Productivity Costs After Multiple Imputation for EG and CG Over 9 Months

Productivity Cost Category	EG (n = 178)			CG (n = 179)			Mean Cost Difference
	People, No. ^a	Mean Hours ^b	Mean Cost	People, No. ^a	Mean Hours ^b	Mean Cost	
Participants with paid job, No.							
3 months	76	118.9	—	82	112.9	—	—
6 months	74	119.9	—	78	108.4	—	—
9 months	68	104.3	—	69	97.7	—	—
Long-term absenteeism							
3 months	10	6.3	€174	6	4.6	€155	€19
6 months	5	1.2	€41	3	4.2	€115	−€74
9 months	4	1.9	€38	0	0.0	€0	€38
Short-term absenteeism							
3 months	31	17.6	€586	33	18.2	€532	€54
6 months	18	5.9	€194	36	19.0	€591	−€397
9 months	23	12.8	€422	28	15.9	€514	−€92
Presenteeism							
3 months	30	1.5	€45	34	2.9	€79	−€34
6 months	15	2.0	€59	44	1.5	€46	€13
9 months	20	1.3	€28	32	1.4	€43	−€15

NOTE. Country-specific friction period is applied (Data Supplement, Table S5).

Abbreviation: EG, exercise group.

^aNumber of participants with an average health care usage >0 after multiple imputation.

^bAverage hours of all patients over 3-month period, including participants who indicated 0 hours.

Cost-Utility Analyses

The results of the cost-utility base case and scenario analyses are presented in Table 4. Both base case analyses (one-on-one and one-on-four supervision) showed cost-savings (probability of 54% and 88%, respectively) and increased QALYs (probability of 79% for both scenarios) for EG and are, therefore, considered dominant (ie, the intervention is more effective and less costly; Data Supplement, Table S1) compared with CG. The CE-plane showed that with one-on-one supervision, 44% of the cost-effect pairs were in the southeast quadrant, representing cost-savings and higher effectiveness of the exercise program, and 35% were in the northeast (NE) quadrant, representing higher costs and

higher effectiveness (Table 4 and Fig 2A). With one-on-four supervision, 70% were in the southeast quadrant and 9% in the NE quadrant. The CEAC indicated that the probability of one-on-one supervised exercise being cost-effective compared with control was 65% and 77% when the WTP-threshold was set at €20,000 and €80,000/QALY (Fig 2A), respectively, and 91% and 92% for one-on-four supervision (Fig 2B).

Scenario Analyses

The scenario analysis with one-on-four supervision from a health care perspective was dominant compared with CG (Table 4); one-on-one supervision from a health care

TABLE 3. Effects of the EFFECT Exercise Program on Utilities and QALYs

Effect	EG (n = 178), Mean (SE)	CG (n = 179), Mean (SE)	Mean Between-Group Difference, 95% CI	ES
Utility at baseline	0.887 (0.008)	0.871 (0.010)	0.016 (−0.010 to 0.042)	0.13
Utility at 3 months	0.837 (0.019)	0.816 (0.020)	0.020 (−0.034 to 0.074)	0.16
Utility at 6 months	0.797 (0.020)	0.749 (0.026)	0.048 (−0.016 to 0.112)	0.39
Utility at 9 months	0.744 (0.027)	0.715 (0.027)	0.029 (−0.049 to 0.106)	0.23
QALY, unadjusted	0.610 (0.012)	0.587 (0.013)	0.024 (−0.014 to 0.061)	—
QALY, adjusted ^a	0.606 (0.011)	0.591 (0.012)	0.013 (−0.019 to 0.046)	—

NOTE. Suggested interpretation by Cohen: ES <0.2, no difference; ES of 0.2-0.5, small difference; ES of 0.5-0.8, medium difference; and ES 0.8 or more, large difference.

Abbreviations: CG, control group; EG, exercise group; ES, Cohen's effect size; QALY, quality-adjusted life-year.

^aAdjusted for baseline utility, treatment center, and line of treatment.

TABLE 4. Results of the Cost-Utility Scenario Analyses

									CE Plane ^a			
Type of Analysis	Mean Cost (SE)		ΔC	95% CI	Mean QALY (SE)	ΔE	95% CI	ICER	NE	SE	SW	NW
Base case analyses	One-on-one group size, societal perspective											
	EG	€9,553 (€652)	−€163	−€2,228 to €1,901	0.61 (0.01)	0.01	−0.02 to 0.05	Dominant	35%	44%	12%	10%
	CG	€9,716 (€862)		Reference	0.59 (0.01)		Reference					
	One-on-four group size, societal perspective											
	EG	€8,467 (€649)	−€1,249	−€3,315 to €817	0.61 (0.01)	0.01	−0.02 to 0.05	Dominant	9%	70%	18%	3%
	CG	€9,716 (€863)		Reference	0.59 (0.01)		Reference					
Scenario analyses	One-on-one group size, health care perspective											
	EG	€7,142 (€403)	€548	−€909 to €2,004	0.61 (0.01)	0.01	−0.02 to 0.05	€40,723	61%	18%	5%	16%
	CG	€6,594 (€626)		Reference	0.59 (0.01)		Reference					
	One-on-four group size, health care perspective											
	EG	€6,056 (€397)	−€538	−€1,990 to €915	0.61 (0.01)	0.01	−0.02 to 0.05	Dominant	18%	61%	16%	5%
	CG	€6,594 (€626)		Reference	0.59 (0.01)		Reference					
	Trial-based group size, societal perspective											
	EG	€8,959 (€652)	−€756	−€1,827 to €1,315	0.61 (0.01)	0.01	−0.02 to 0.05	Dominant	18%	61%	15%	5%
	CG	€9,716 (€864)		Reference	0.59 (0.01)		Reference					

NOTE. CI estimated using the nonparametric bootstrap (bias-corrected intervals).

Abbreviations: ΔC, difference in costs over the 9-month intervention period (EG–CG, 2021 €); ΔE, difference in effect over the 9-month intervention period (EG–CG, QALYs); CE, plane, cost-effectiveness plane; CG, control group; EG, exercise group; ICER, incremental cost-effectiveness ratio; NE, northeast quadrant; NW, northwest quadrant; QALY, quality-adjusted life-year; SE, southeast quadrant; SW, southwest quadrant.

^aPercentages might not add up to 100% because of rounding.




FIG 2. Cost-effectiveness plane (left) and cost-effectiveness acceptability curve (right) for (A) one-on-one supervision and (B) one-on-four supervision. WTA = WTP: points in the southwest quadrant are included if (difference in costs/difference in QALY) > WTP. WTA = 0: points in the southwest quadrant are excluded. The cost-effectiveness plane displays the difference in costs (vertical axis) and difference in QALY (QALYs, horizontal axis) between the intervention (EG; 9-month exercise program) and CG after 5,000 bootstrap iterations. Every dot indicates the difference in costs and QALYs (ie, a cost-effect pair) between EG and CG of one bootstrap iteration, thus representing the uncertainty of the analysis. The red dot indicates the difference in costs and QALYs between EG and CG before bootstrapping, while the shades of blue represent the density of bootstrap iterations (lighter = higher density). The percentage of bootstrap iterations per quadrant is displayed in the figures and Table 4. If the cost-effect pair falls within the NW or southeast quadrant, the choice between EG and CG is clear. In the southeast quadrant, EG is more effective and less costly compared with CG, and therefore dominates CG. In the NW quadrant, the opposite is true. In the SW and NE quadrants, the choice depends on the maximum cost-effectiveness ratio one is willing to accept. The cost-effectiveness acceptability curve displays the probability of cost-effectiveness of EG for every WTP threshold. This probability is based on the number of bootstrap iterations that are considered cost-effective at a certain threshold (ie, either lower costs and higher effectiveness for EG, or higher costs and higher effectiveness, whereby the costs per QALY gained are lower than the WTP threshold). The higher the WTP threshold, the higher the probability of cost-effectiveness. The primary one-on-four scenario (continued on following page)

FIG 2. (Continued). is cost-effective at lower WTP thresholds than the one-on-one scenario. CG, control group; EG, exercise group; NE, northeast quadrant; NW, northwest quadrant; QALY, quality-adjusted life-year; SE, southeast quadrant; SW, southwest quadrant; WTA, willingness-to-accept (willingness to accept lower QALYs if it comes with lower costs); WTP, willingness-to-pay (willingness to pay for additional QALYs).

perspective resulted in incremental costs of €548, with a probability of cost-effectiveness of 36% and 63% at a WTP threshold of €20,000 and €80,000/QALY, respectively (Data Supplement, Fig S2). When assuming that the exercise program would be implemented using the group size as applied in the trial (ranging from one to five participants per session, depending on the country), the cost-savings from a societal perspective were €756 (ie, between the cost-savings observed for the two base case analyses). The results of the additional scenario analyses, conducted from a societal perspective and assuming all patients were Dutch (Data Supplement, Table S8), were similar to the base case analyses.

DISCUSSION

Supervised exercise for patients with mBC is dominant compared with CG, thus resulting in an increase in QALYs at similar or lower costs. Although the mean exercise program costs were €1,696 over 9 months when supervised one-on-one and €609 when supervised one-on-four, these costs were offset by savings in health care and productivity costs. Hence, supervised exercise for patients with mBC has a 65%-91% probability to be cost-effective at a WTP threshold of €20,000/QALY.

To the best of our knowledge, the current study is the first economic evaluation of supervised exercise in patients with mBC. Other RCTs ($n = 4$) have investigated the cost-effectiveness of supervised exercise in patients with BC receiving curative treatment and applied different exercise interventions. In line with our study, van Waart et al³⁵ found that a moderate- to high-intensity supervised exercise program could be considered cost-effective (WTP = €80,000/QALY: 79% v 77% in our study) compared with usual care. In the other three RCTs, the probability of exercise being cost-effective was low.³⁶⁻³⁸ These studies involved either a lower intensity or shorter exercise program compared with PREFERABLE-EFFECT, had no or large group-based ($n = 8$ participants) supervision, or a different comparator (ie, relaxation and flexibility program or personalized dietary and physical activity counseling), which might explain the divergent findings.

Our findings indicate that the largest cost-savings occurred in home care, productivity losses, day treatments, and hospital admissions. Importantly, savings were found for short-term absenteeism, which suggests higher productivity because of better health. This is in line with earlier findings on favorable effects of exercise on clinically relevant outcomes, including fatigue, pain, dyspnea, physical fitness, physical functioning,

role functioning, and social functioning.⁷ This suggests that participants in EG were better able to engage in activities of daily living with less impact from their disease and treatment. Previous observational studies have shown that lower symptom burden and better physical functioning positively affect health care use and productivity.^{39,40} In the abovementioned studies in early BC, no overall cost-savings were found. For some cost categories, smaller cost-savings were observed, and van Waart et al also found cost-savings for home care.³⁵⁻³⁸

In PREFERABLE-EFFECT, beneficial effects of exercise on disease-specific HR-QoL and physical fatigue were found for patients with mBC, measured using the EORTC QLQ-C30 and EORTC-FA12, respectively.⁷ In this economic evaluation, the EQ-5D-5L was used to assess HR-QoL. No significant differences were found between groups, but the study was also not powered to this outcome. Utility scores were higher for EG at all time points, resulting in an adjusted QALY difference corresponding to 5 days in perfect health in favor of EG. Although fatigue affects EQ-5D-5L utility scores,^{41,42} this generic questionnaire is not designed to capture the specific impact of changes in cancer-related fatigue on HR-QoL.^{43,44} Finally, as suggested by a recent systematic review, cost-effectiveness might be higher with a longer time horizon than the 9 months of the PREFERABLE-EFFECT trial.¹² Since long-term effects of the exercise program on the prognosis of our study population are uncertain, we cannot draw inferences on long-term health economic effects.

Cost-effectiveness, in addition to clinical outcomes, are essential to make informed decisions on implementation of individually or group-based supervised exercise interventions. In this study, EG size varied, but was kept constant in the two base case analyses, assuming group size does not affect QALYs. Research suggests that supervised group-based exercise might have a stronger positive effect on HR-QoL compared with individual supervision, while exercise effects on fatigue and physical fitness are similar.⁴⁵⁻⁴⁷ Regardless, the analyses indicate that both individually and group-based supervised exercise are cost-effective compared with control, with group-based exercise having larger cost-savings. These findings support expanding the existing ACSM⁵ and ASCO⁶ guidelines, which advocate for the integration of exercise as an integral component of supportive care for patients during and after curative cancer treatment, to include patients with mBC.

Strengths of this study are its multinational, randomized, and pragmatic design with a relatively large sample size. Pragmatic trials better reflect daily conditions, making them more suitable for clinical and policy decision making.

Limitations of our study are that participants were not blinded to group assignment because of the nature of the intervention, potentially leading to an underestimation of the intervention effect as control participants might have increased their physical activity levels. Since CG only increased their light- and moderate-intensity physical activities (data shown in the study by Hiensch et al⁷), knowledge of group assignment was assumed to have had minimal impact on observed effects. Although efforts were made to collect country-specific unit costs to better reflect absolute and relative price differences, variation in methodology contribute substantially to differences in unit costs.⁴⁸ Therefore, only the results of the medical basket approach have been presented. Further research is needed to determine the impact of country-specific unit costs and variations in methodology on the outcomes of cost-effectiveness results. The impact of varying unit costs was assessed by including a scenario from the Dutch perspective (Data Supplement, Table S8), which showed similar cost-effectiveness outcomes. Finally, the estimated overhead

costs might not fully capture the variability in overhead costs across different settings (eg, within and outside hospital setting, urban v rural facilities, private v public facilities, or differences across health care systems). Therefore, actual overhead costs may vary.

In conclusion, to our knowledge, this multinational study is the first to show that for patients with mBC, supervised exercise is associated with higher QALYs and similar costs or cost-savings compared with control. The additional costs of the exercise program are offset by a reduction in health care resource use and productivity losses. Both individually supervised and group-based supervised interventions are cost-effective, with the latter showing dominance because of higher cost-savings. These findings can inform reimbursement of exercise supervised by an exercise specialist as part of standard clinical care for patients with mBC. If group-based exercise is not feasible, our results indicate that individually supervised exercise programs also represent a cost-effective option compared with control.

AFFILIATIONS

¹Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

²Division of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, A Partnership Between DKFZ and University Medical Center Heidelberg, Heidelberg, Germany

³Department of Molecular and Cellular Sports Medicine, Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany

⁴Department for Molecular and Cellular Sports Medicine, German Sport University Cologne, Cologne, Germany

⁵Gipuzkoa Cancer Unit, OSID-Onkologikoa, BioGipuzkoa, Osakidetza, San Sebastian, Spain

⁶Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia

⁷Department of Laboratory Medicine, Karolinska Institutet and Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden

⁸Working Group Exercise Oncology, Division of Medical Oncology, Heidelberg University Hospital and NCT Heidelberg, A Partnership Between DKFZ and University Medical Center Heidelberg, Heidelberg, Germany

⁹Heidelberg University Hospital and NCT Heidelberg, A Partnership Between DKFZ and University Medical Center Heidelberg, Heidelberg, Germany

¹⁰Division of Psychosocial Research and Epidemiology & Center for Quality of Life, Netherlands Cancer Institute, Amsterdam, the Netherlands

¹¹National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany

¹²Department of Oncology-Pathology, Karolinska Institutet and Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden

¹³Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

¹⁴Breast Cancer Center, Netherlands Cancer Institute, Amsterdam, the Netherlands

¹⁵Royal Melbourne Hospital, Melbourne, Victoria, Australia

¹⁶Peter MacCallum Cancer Center, Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia

¹⁷Cabrini Cancer Institute, Cabrini Health, Melbourne, Victoria, Australia

¹⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Gynecology and Obstetrics, Breast Center, CIO

¹⁹Greater Poland Cancer Centre, Poznan, Poland

²⁰Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands

²¹Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland

²²Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia

²³Karolinska Institutet and Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden

CORRESPONDING AUTHOR

Anne M. May, PhD; Twitter: @annemariamay; e-mail: a.m.may@umcutrecht.nl.

EQUAL CONTRIBUTION

A.E.M.S. and A.E.H. are first authors.

PRIOR PRESENTATION

Presented in part at the 2024 ASCO Annual Meeting, Chicago, IL, May 31-June 4, 2024.

SUPPORT

Supported by the European Union's Horizon 2020 research and innovation program (No. 825677) and the National Health and Medical Research Council of Australia (2018/GNT1170698).

CLINICAL TRIAL INFORMATION

[NCT04120298](https://clinicaltrials.gov/ct2/show/study/NCT04120298)

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO-24-01441>.

DATA SHARING STATEMENT

A data sharing statement provided by the authors is available with this article at DOI <https://doi.org/10.1200/JCO-24-01441>.

AUTHOR CONTRIBUTIONS

Conception and design: Anouk E. Hiensch, Evelyn M. Monninkhof, Martina E. Schmidt, Dorothea Clauss, Jon Belloso, Helene Rundqvist, Jana Müller, Elsken van der Wall, Neil K. Aaronson, Elzbieta Senkus, Ander Urruticoechea, Eva M. Zopf, Wilhelm Bloch, Martijn M. Stuiver, Yvonne Wengstrom, Karen Steindorf, Anne M. May

Financial support: Anne M. May, Martijn M. Stuiver, Karen Steindorf, Yvonne Wengstrom, Wilhelm Bloch, Eva M. Zopf, Ander Urruticoechea, Joachim Wiskemann, Elzbieta Senkus

Provision of study materials or patients: Carlo Fremd, Renske Altena, Rhodé M. Bijlsma, Gabe Sonke, Ainhara Lahuerta, G. Bruce Mann, Prudence A. Francis, Gary Richardson, Wolfram Malter, Joanna Kufel-Grabowska, Elsken van der Wall, Elzbieta Senkus, Ander Urruticoechea

Collection and assembly of data: Anouk E. Hiensch, Evelyn M. Monninkhof, Martina E. Schmidt, Dorothea Clauss, Nadira Gunasekara, Jon Belloso, Mark Trevaskis, Helene Rundqvist, Jana Müller, Maike G. Sweegers, Neil K. Aaronson, Elzbieta Senkus, Ander Urruticoechea,

Eva M. Zopf, Wilhelm Bloch, Martijn M. Stuiver, Yvonne Wengstrom, Karen Steindorf, Anne M. May

Data analysis and interpretation: Aniek E.M. Schouten, Anouk E. Hiensch, Geert W.J. Frederix, Joachim Wiskemann, Carlo Fremd, Renske Altena, Rhodé M. Bijlsma, Gabe Sonke, Ainhara Lahuerta, G. Bruce Mann, Prudence A. Francis, Gary Richardson, Wolfram Malter, Joanna Kufel-Grabowska, Miriam P. van der Meulen, Anne M. May

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

The authors thank all participants, all involved exercise professionals, and all professional staff at all participating centers in Germany (Heidelberg University Hospital/German Cancer Research Center [DKFZ]/National Center for Tumor Diseases [NCT] Heidelberg, and German Sport University Cologne [DSHS]), the Netherlands (University Medical Center Utrecht [UMCU], the Netherlands Cancer Institute [NKI], Diaconessenhuis Utrecht, Alexander Monro Ziekenhuis), Poland (Greater Poland Cancer Center [GPCC]), Spain (Onkologikoa [ONK]), Sweden (Karolinska Institutet [KI] and Karolinska University Hospital), and Australia (Australian Catholic University [ACU], Peter MacCallum Cancer Center, Royal Melbourne Hospital, Cabrini Health) for their invaluable participation in this trial. We also thank our project partner the European Breast Cancer Coalition Europa Donna for their contribution to the PREFERABLE-EFFECT randomized controlled trial.

REFERENCES

- Swain SM, Miles D, Kim S, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. *Lancet Oncol* 21:519-530, 2020
- Cortes J, Hugo HS, Cescon DW, et al: Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. *N Engl J Med* 387:217-226, 2022
- Hortobagyi GN, Stemmer GN, Burris HA, et al: Overall survival with ribociclib plus letrozole in advanced breast cancer. *N Engl J Med* 386:942-950, 2022
- Cardoso F, Spence D, Mertz S, et al: Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). *Breast* 39:131-138, 2018
- Campbell KL, Winters-Stone KM, Wiskemann J, et al: Exercise guidelines for cancer survivors: Consensus statement from International Multidisciplinary Roundtable. *Med Sci Sports Exerc* 51:2375-2390, 2019
- Ligibel JA, Bohlke K, May AM, et al: Exercise, diet, and weight management during cancer treatment: ASCO guideline. *J Clin Oncol* 40:2491-2507, 2022
- Hiensch AE, Depenbusch J, Schmidt ME, et al: Supervised, structured and individualized exercise in metastatic breast cancer: A randomized controlled trial. *Nat Med* 30:2957-2966, 2024
- Gogate A, Wheeler SB, Reeder-Hayes KE, et al: Projecting the prevalence and costs of metastatic breast cancer from 2015 through 2030. *JNCI Cancer Spectr* 5:pkab063, 2021
- Chen S, Cao Z, Prettnier K, et al: Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. *JAMA Oncol* 9:465-472, 2023
- Sullivan R, Peppercorn J, Sikora K, et al: Delivering affordable cancer care in high-income countries. *Lancet Oncol* 12:933-980, 2011
- Gallagher A, Shersher V, Mortimer D, et al: The cost-effectiveness of adjunctive lifestyle interventions for the management of cancer: A systematic review. *Appl Health Econ Health Policy* 21:225-242, 2023
- Wang Y, McCarthy AL, Hayes SC, et al: Economic evaluation of exercise interventions for individuals with cancer: A systematic review. *Prev Med* 172:107491, 2023
- Hiensch AE, Monninkhof EM, Schmidt ME, et al: Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: The EFFECT study. *Trials* 23:610, 2022
- Husereau D, Drummond M, Augustovski F, et al: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. *Int J Technol Assess Health Care* 38:e13, 2022
- Pickard AS, Wilke CT, Lin HW, et al: Health utilities using the EQ-5D in studies of cancer. *Pharmacoeconomics* 25:365-384, 2007
- Feng YS, Kohlmann T, Janssen MF, et al: Psychometric properties of the EQ-5D-5L: A systematic review of the literature. *Qual Life Res* 30:647-673, 2021
- Janssen MF, Pickard AS, Golicki D, et al: Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. *Qual Life Res* 22:1717-1727, 2013
- Jones K, Weatherly H, Birch S, et al: Unit Costs of Health and Social Care 2022 Manual. 2023. <https://www.pssru.ac.uk/unitcostsreport/PersonalSocialServicesResearchUnit&CentreofHealthEconomics>
- Zorginstituut Nederland: Guideline for conducting economic evaluations in health care [Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg]. 2016. <https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg>
- Institute for Medical Technology Assessment: iMTA Medical Consumption Questionnaire. Institute for Medical Technology Assessment. <https://www.imta.nl/questionnaires/imcq/Updatedn.d>
- Oliva-Moreno J, Peña-Longobardo LM, García-Mochón L, et al: The economic value of time of informal care and its determinants (The CUIDARSE Study). *PLoS One* 14:e0217016, 2019
- Institute for Medical Technology Assessment: iMTA Productivity Cost Questionnaire. Institute for Medical Technology Assessment. <https://www.imta.nl/questionnaires/ipcq>
- OECD: Labour compensation per hour worked (annual growth rate (%)). 2023. <https://data.oecd.org/lprdy/labour-compensation-per-hour-worked.htm>
- Devlin N, Finch AP, Parkin D: Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide. Cham, Switzerland, Springer International Publishing, 2022, pp 213-233
- Ludwig K, Graf von der Schulenburg JM, Greiner W: German value set for the EQ-5D-5L. *Pharmacoeconomics* 36:663-674, 2018
- Drummond MF, Sculpher MJ, Claxton K, et al: Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, 2015, pp 9
- White IR, Royston P, Wood AM: Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med* 30:377-399, 2011
- Ben AJ, van Dongen JM, El Alili M, et al: Conducting trial-based economic evaluations using R: A tutorial. *Pharmacoeconomics* 41:1403-1413, 2023
- Cohen J: Statistical Power Analysis for the Behavioral Sciences. Academic Press, 2013
- The Agency for Health Technology Assessment and Tariff System: Health Technology Assessment Guidelines Version 3.0. <https://www.aotm.gov.pl/en/guidelines/Published2016>
- Sampson C, Zamora B, Watson S, et al: Supply-side cost-effectiveness thresholds: Questions for evidence-based policy. *Appl Health Econ Health Policy* 20:651-667, 2022
- Barra M, Broqvist M, Gustavsson E, et al: Severity as a priority setting criterion: Setting a challenging research agenda. *Health Care Anal* 28:25-44, 2020
- Kovács S, Németh B, Erdősi D, et al: Should Hungary pay more for a QALY gain than higher-income Western European Countries? *Appl Health Econ Health Policy* 20:291-303, 2022
- Zorginstituut Nederland: Guideline for performing health economic evaluations. Revised version 2024 [Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Herzien versie 2024]. 2024. <https://www.zorginstituutnederland.nl/publicaties/publicatie/2024/01/16/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg>

35. van Waart H, van Dongen JM, van Harten WH, et al: Cost-Utility and cost-effectiveness of physical exercise during adjuvant chemotherapy. *Eur J Health Econ* 19:893-904, 2018
36. Perrier L, Foucaut A, Morelle M, et al: Cost-effectiveness of an exercise and nutritional intervention versus usual nutritional care during adjuvant treatment for localized breast cancer: The PASAPAS randomized controlled trial. *Support Care Cancer* 28:2829-2842, 2020
37. May AM, Bosch MJC, Velthuis MJ, et al: Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: The randomised PACT study. *BMJ Open* 7:e012187, 2017
38. Haines TP, Sinnamon P, Wetzig NG, et al: Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation. *Breast Cancer Res Treat* 124:163-175, 2010
39. Lage DE, El-Jawahri A, Fuh C, et al: Functional impairment, symptom burden, and clinical outcomes among hospitalized patients with advanced cancer. *J Natl Compr Canc Netw* 18:747-754, 2020
40. Kurtz ME, Kurtz JC, Given CW, et al: Utilization of services among elderly cancer patients—Relationship to age, symptoms, physical functioning, comorbidity, and survival status. *Ethn Dis* 15:17-22, 2005 (suppl 2)
41. Borchert K, Jacob C, Wetzel N, et al: Application study of the EQ-5D-5L in oncology: Linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry. *Health Econ Rev* 10:40, 2020
42. Färkkilä N, Torvinen S, Roine RP, et al: Health-related quality of life among breast, prostate, and colorectal cancer patients with end-stage disease. *Qual Life Res* 23:1387-1394, 2014
43. Spronk I, Polinder S, Bonsel GJ, et al: The relation between EQ-5D and fatigue in a Dutch general population sample: An explorative study. *Health Qual Life Outcomes* 19:135, 2021
44. Efthymiadou O, Mossman J, Kanavos P: Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients. *Health Policy* 123:159-165, 2019
45. Yamada PM, Teranishi-Hashimoto C, Bantum EO: Paired exercise has superior effects on psychosocial health compared to individual exercise in female cancer patients. *Support Care Cancer* 29: 6305-6314, 2021
46. Leach HJ, Covington KR, Voss C, et al: Effect of group dynamics-based exercise versus personal training in breast cancer survivors. *Oncol Nurs Forum* 46:185-197, 2019
47. Rosario PM, Naumann F, Martin E: The effects of an individual versus a group delivered exercise and counselling intervention on fatigue in breast cancer survivors. *J Sci Med Sport* 14:e116-e117, 2011
48. Mayer S, Fischer C, Zechmeister-Koss I, et al: Are unit costs the same? A case study comparing different valuation methods for unit cost calculation of general practitioner consultations. *Value Health* 23:1142-1148, 2020

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

Geert W.J. Frederix

Consulting or Advisory Role: Illumina (Inst)

Joanna Kufel-Grabowska

Consulting or Advisory Role: Novartis, AstraZeneca, Lilly, Roche, MSD

Speakers' Bureau: Novartis, AstraZeneca, Lilly, Roche, MSD, Swixx BioPharma

Expert Testimony: Roche, MSD, Lilly

Travel, Accommodations, Expenses: MSD, Roche, Swixx BioPharma

Carlo Fremd

Honoraria: Roche, Pfizer, AstraZeneca, GlaxoSmithKline/Novartis

Consulting or Advisory Role: Roche, Pfizer, Eisai, MSD

Research Funding: Roche/Genentech, VeracYTE

Joachim Wiskemann

Honoraria: Lilly, Amgen, Janssen-Cilag, Servier

Gabe Sonke

Consulting or Advisory Role: Novartis (Inst), Seagen (Inst), Biovica (Inst)

Research Funding: Merck Sharp & Dohme (Inst), Agendia (Inst), AstraZeneca/Merck (Inst), Roche (Inst), Novartis (Inst), Seagen (Inst)

G. Bruce Mann

Stock and Other Ownership Interests: CSL Limited, PreludeDx (I)

Research Funding: PreludeDx (Inst), Optican Pty Ltd (Inst), Ferronova (Inst), Hologic (Inst)

Prudence A. Francis

Honoraria: Lilly, Amplitude Health

Gary Richardson

Research Funding: Bristol Myers Squibb (Inst), Roche/Genentech (Inst), AstraZeneca (Inst), Merck (Inst), Takeda (Inst), BeiGene (Inst), Pfizer (Inst), CBT Pharmaceuticals (Inst), Corvus Pharmaceuticals (Inst), Novotech (Inst), Fosun Pharma (Inst), Shanghai Henlius Biotech (Inst), Five Prime Therapeutics (Inst), Suzhou Alphamab (Inst), Boehringer

Ingelheim (Inst), Adagene (Inst), Bio-Thera Solutions (Inst), ChemoCentryx (Inst), Curon Biopharmaceutical (Inst), D3 Bio (Inst), InventisBio (Inst), Senz Oncology (Inst), Genfleet Therapeutics (Inst), Gene Quantum (Inst), Shanghai Henlius Biotech (Inst), Keythera Pharmaceuticals (Inst), LaNova Australia (Inst), Medicenna (Inst), Minghui Pharmaceutical (Inst), Neoleukin Therapeutics (Inst), PharmAbcine (Inst), RemeGen (Inst), Seagen (Inst), Surface Oncology (Inst), Eucure Biopharma (Inst), Janssen Oncology (Inst), ImmunGen Inc (Inst), Imugene (Inst), Therapim (Inst), Zentalis (Inst), Agenus (Inst), D3 Bio (Wuxi) Co, Ltd (Inst)

Wolfram Malter

Honoraria: Roche

Consulting or Advisory Role: Pfizer

Travel, Accommodations, Expenses: Celgene, Novartis

Elzbieta Senkus

Stock and Other Ownership Interests: Ataraxis

Honoraria: AstraZeneca, Curio Science, Lilly, Gilead Sciences, High5md, MSD, Novartis, Pfizer, Swixx BioPharma

Consulting or Advisory Role: AstraZeneca, Lilly, Gilead Sciences, Novartis, Pfizer, Roche

Travel, Accommodations, Expenses: AstraZeneca, Gilead Sciences, Novartis

Other Relationship: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, OBI Pharma, Pfizer, Roche, Astellas Pharma, Gilead Sciences, Seagen

Ander Urruticoechea

Consulting or Advisory Role: InProTher, Ellipses Pharma

Travel, Accommodations, Expenses: Roche/Genentech, Pfizer, Gilead Sciences, Astra Zeneca/Daiichi Sankyo, Novartis, Pierre Fabre

Karen Steindorf

Honoraria: Murgpark Kuppenheim Physiostraining, Adviva Medical Technics, Takeda

No other potential conflicts of interest were reported.